Amporin Pharmaceuticals

Amporin Pharmaceuticals AG is an emerging Swiss biotech company based in Basel and founded in 2024 by a small team of ex-Pharma CNS drug discovery and development professionals. We are developing a breakthrough new class of small molecule "amyloid pore inhibitors” that can uniquely protect cell membranes and repair the holes formed by toxic soluble misfolded protein oligomers in over 50 deadly degenerative diseases, including ALS, Alzheimer's, Parkinson's, Huntington's, type II diabetes, and many rare degenerative diseases. Together, these diseases affect over half a billion people and kill 3.6 million people around the world each year, at a total cost to society of USD 3 trillion per year. Moreover, these diseases are growing rapidly with the aging population, yet there are still no effective treatments that can stop or reverse the underlying process of degeneration. By uniquely targeting the common fundamental pathogenic mechanism of amyloid pore formation in all these diseases, our molecules can effectively repair cell membranes and allow diseased cells to fully recover and restore homeostasis. Our vision is to develop the first acute oral disease-modifying treatments to cure 6 major degenerative diseases with a simple pill, starting with Parkinson’s disease and ALS. Amporin won 3rd place in the Venture.ch Swiss national startup competition, and won the final stage of Venture Kick shortly shortly after the company was founded in 2024. The company was selected as a Venture Leader Biotech to represent Switzerland's top biotech startups in 2025.